Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C95124
http://purl.obolibrary.org/obo/NCIT_C95124
|
|---|---|
| Preferred Name | Lenvatinib |
| Definitions |
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis. |
|---|---|
| prefLabel | Lenvatinib
|
| label | Lenvatinib
|
| Has_Salt_Form | |
| code | C95124
|
| Has_Target | |
| prefixIRI | NCIT:C95124
|
| in_subset |
See more
See less
|
| Display_Name | Lenvatinib
|
| Preferred_Name | Lenvatinib
|
| FDA_UNII_Code | EE083865G2
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C21H19ClN4O4
|
| Maps_To | Lenvatinib
|
| CAS_Registry | 417716-92-8
|
| PubMedID_Primary_Reference | 18765537
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Accepted_Therapeutic_Use_For | unresectable hepatocellular carcinoma (HCC)
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2986924
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |